NO934609D0 - Nye preparater basert pa derivater fra taxanklassen - Google Patents

Nye preparater basert pa derivater fra taxanklassen

Info

Publication number
NO934609D0
NO934609D0 NO934609A NO934609A NO934609D0 NO 934609 D0 NO934609 D0 NO 934609D0 NO 934609 A NO934609 A NO 934609A NO 934609 A NO934609 A NO 934609A NO 934609 D0 NO934609 D0 NO 934609D0
Authority
NO
Norway
Prior art keywords
derivatives
preparations based
taxane class
new preparations
taxane
Prior art date
Application number
NO934609A
Other languages
English (en)
Other versions
NO307205B1 (no
NO934609L (no
Inventor
Jean-Pierre Bastart
Thierry Dupechez
Jean-Louis Fabre
Original Assignee
Rhone Poulanc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9414814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO934609(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulanc Rorer Sa filed Critical Rhone Poulanc Rorer Sa
Publication of NO934609L publication Critical patent/NO934609L/no
Publication of NO934609D0 publication Critical patent/NO934609D0/no
Publication of NO307205B1 publication Critical patent/NO307205B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
NO934609A 1991-07-08 1993-12-14 Preparater basert på virkestoffer fra taxanklassen samt perfusjonspreparater inneholdende disse NO307205B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9108527A FR2678833B1 (fr) 1991-07-08 1991-07-08 Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
PCT/FR1992/000624 WO1993000928A1 (fr) 1991-07-08 1992-07-03 Nouvelles compositions a base de derives de la classe des taxanes

Publications (3)

Publication Number Publication Date
NO934609L NO934609L (no) 1993-12-14
NO934609D0 true NO934609D0 (no) 1993-12-14
NO307205B1 NO307205B1 (no) 2000-02-28

Family

ID=9414814

Family Applications (2)

Application Number Title Priority Date Filing Date
NO934609A NO307205B1 (no) 1991-07-08 1993-12-14 Preparater basert på virkestoffer fra taxanklassen samt perfusjonspreparater inneholdende disse
NO934610A NO307206B1 (no) 1991-07-08 1993-12-14 Preparater på basis av virkestoffer fra taxanklassen samt perfusjonspreparat inneholdende disse

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO934610A NO307206B1 (no) 1991-07-08 1993-12-14 Preparater på basis av virkestoffer fra taxanklassen samt perfusjonspreparat inneholdende disse

Country Status (28)

Country Link
US (1) US5403858A (no)
EP (4) EP0593601B1 (no)
JP (2) JPH06507914A (no)
KR (1) KR0136722B1 (no)
AT (2) ATE147992T1 (no)
CA (2) CA2102778C (no)
CZ (1) CZ280965B6 (no)
DE (3) DE69223624T2 (no)
DK (2) DK0593601T3 (no)
ES (2) ES2110003T3 (no)
FI (2) FI111807B (no)
FR (1) FR2678833B1 (no)
GE (1) GEP19991517B (no)
GR (2) GR3022355T3 (no)
HK (1) HK1006207A1 (no)
HU (1) HU217839B (no)
IE (2) IE80461B1 (no)
MX (2) MX9203959A (no)
NO (2) NO307205B1 (no)
PL (1) PL169372B1 (no)
RU (1) RU2134123C1 (no)
SE (1) SE0593656E5 (no)
SG (1) SG80541A1 (no)
SK (1) SK279946B6 (no)
TW (2) TW495362B (no)
WO (2) WO1993000928A1 (no)
YU (1) YU48913B (no)
ZA (1) ZA924999B (no)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) * 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
GB2269319B (en) * 1992-08-03 1997-04-09 Bristol Myers Squibb Co Methods for administration of taxol
ATE274347T1 (de) * 1992-11-27 2004-09-15 Mayne Pharma Usa Inc Stabile injizierbare paclitaxel lösung
US5684169A (en) * 1992-11-27 1997-11-04 Ensuiko Sugar Refining Co., Ltd. Cyclodextrin inclusion complex of taxol, and method for its production and its use
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物,その製造法と用途
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
DK0797988T3 (da) * 1993-07-19 2009-05-11 Univ British Columbia Anti-angiogene præparater og fremgangsmåder til anvendelse deraf
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
WO1995033490A1 (en) * 1994-06-02 1995-12-14 Enzon, Inc. Method of solubilizing substantially water insoluble materials
WO1996003113A1 (en) * 1994-07-22 1996-02-08 G.D. Searle & Co. Self-emulsifying drug delivery system
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU724842B2 (en) * 1995-12-21 2000-09-28 Genelabs Technologies, Inc. Taxane composition and method
KR100191446B1 (ko) * 1996-05-02 1999-06-15 송영욱 파클리탁셀 함유 전신성 홍반성 낭창치료제
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
CN1177934C (zh) 1997-04-28 2004-12-01 阿文蒂斯药物股份有限公司 腺病毒介导的肿瘤内投送血管生成拮抗剂用于肿瘤的治疗
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
ATE226070T1 (de) * 1997-05-30 2002-11-15 Man Woo Han Taxol enthaltende pharmazeutische injektionslösung
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US20040254635A1 (en) * 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
DE19983660T1 (de) 1998-10-20 2001-09-13 Ben Venue Lab Inc Verfahren zur Aufreinigung von Lösungsmitteln, die bei der Herstellung von pharmazeutischen Zusammensetzungen nützlich sind
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
PT1328213E (pt) 2000-10-16 2005-10-31 Conor Medsystems Inc Dispositivo medico expansivel para a administracao de um agente benefico
PL203300B1 (pl) 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
EP1337273A2 (en) * 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US6964680B2 (en) * 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
US20040073294A1 (en) * 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
KR20020079239A (ko) * 2001-04-14 2002-10-19 이언식 학습기
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US20040249443A1 (en) * 2001-08-20 2004-12-09 Shanley John F. Expandable medical device for treating cardiac arrhythmias
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
JP2005515187A (ja) * 2001-11-26 2005-05-26 スーパージェン インコーポレイテッド ポリオキシエチル化ひまし油を使用する医薬組成物の調製方法
US20030101058A1 (en) * 2001-11-26 2003-05-29 Kenneth Liou Voice barcode scan device
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
PT1509256E (pt) * 2002-05-24 2009-10-15 Angiotech Int Ag Composições e métodos de revestimento de implantes médicos
US8313760B2 (en) * 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
WO2004026174A2 (en) * 2002-09-20 2004-04-01 Conor Medsystems, Inc. Expandable medical device with openings for delivery of multiple beneficial agents
US20040127976A1 (en) * 2002-09-20 2004-07-01 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
EP1596825A2 (en) 2003-02-03 2005-11-23 Neopharm, Inc. Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs
EP2272544A1 (en) 2003-03-28 2011-01-12 Conor Medsystems, Inc. Implantable medical device with beneficial agent concentration gradient
US7169179B2 (en) * 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7785653B2 (en) * 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
CA2536188A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
KR20080030024A (ko) 2005-06-17 2008-04-03 호스피라 오스트레일리아 피티와이 리미티드 도세탁셀의 약제학적 액상제제
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
WO2008026048A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Stable injectable pharmaceutical compositions of docetaxel
EP1946747A1 (en) * 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
NZ581589A (en) * 2007-06-22 2012-10-26 Scidose Llc Solubilized sterile injectable formulation of docetaxel without Tween 80
US20090076127A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched larotaxel
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前-乳劑調配物及其製造與使用之方法
SG185389A1 (en) 2010-05-03 2012-12-28 Teikoku Pharma Usa Inc Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012156999A1 (en) 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
EP2753355B1 (en) 2011-09-08 2018-10-24 New York University Oncolytic herpes simplex virus and therapeutic uses thereof
WO2013096455A1 (en) 2011-12-20 2013-06-27 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
JP2013194009A (ja) * 2012-03-21 2013-09-30 Nipro Corp ドセタキセル製剤
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JP5847942B2 (ja) 2012-07-19 2016-01-27 富士フイルム株式会社 タキサン系活性成分含有液体組成物、その製造方法及び液体製剤
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2014149871A1 (en) 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
TW202214691A (zh) 2014-03-21 2022-04-16 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
CA3027103A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3468599A2 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214335A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
JP6292267B2 (ja) * 2016-09-13 2018-03-14 ニプロ株式会社 ドセタキセル製剤
EP3679925A4 (en) 2017-09-07 2021-04-21 Shenzhen Salubris Pharmaceuticals Co. Ltd PHARMACEUTICAL COMPOSITION OF DOCETAXEL CONJUGATE AND METHOD OF PREPARATION
JP2018115178A (ja) * 2018-03-15 2018-07-26 ニプロ株式会社 ドセタキセル製剤
EP3823608A4 (en) 2018-09-05 2022-05-11 Emcure Pharmaceuticals Limited STABLE READY-TO-USE PHARMACEUTICAL CARMUSTI COMPOSITION
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206221A (en) * 1979-01-03 1980-06-03 The United States Of America As Represented By The Secretary Of Agriculture Cephalomannine and its use in treating leukemic tumors
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof

Also Published As

Publication number Publication date
IE922213A1 (en) 1993-01-13
JPH06507914A (ja) 1994-09-08
SE0593656T6 (no) 1997-01-22
ES2096091T7 (es) 2010-03-31
FI940073A (fi) 1994-01-07
AU666859B2 (en) 1996-02-29
SK1594A3 (en) 1994-10-05
FR2678833A1 (fr) 1993-01-15
JPH06507913A (ja) 1994-09-08
ATE161193T1 (de) 1998-01-15
NO934610D0 (no) 1993-12-14
JP2595458B2 (ja) 1997-04-02
YU67692A (sh) 1995-12-04
US5403858A (en) 1995-04-04
SE0593656E5 (sv) 2009-10-07
EP0593601A1 (fr) 1994-04-27
EP0593601B1 (fr) 1997-12-17
FI940073A0 (fi) 1994-01-07
CA2102777C (fr) 2004-09-07
RU2134123C1 (ru) 1999-08-10
GR3022355T3 (en) 1997-04-30
NO307205B1 (no) 2000-02-28
GEP19991517B (en) 1999-03-05
WO1993000928A1 (fr) 1993-01-21
FI111808B (fi) 2003-09-30
DK0593656T3 (da) 1997-02-10
DE69217056T4 (de) 2009-08-20
EP0593656A1 (fr) 1994-04-27
NO307206B1 (no) 2000-02-28
TW495362B (en) 2002-07-21
FI940074A (fi) 1994-01-07
ATE147992T1 (de) 1997-02-15
DE69217056D1 (de) 1997-03-06
ES2096091T3 (es) 1997-03-01
CA2102777A1 (fr) 1993-01-09
IE922212A1 (en) 1993-01-13
DE69223624T2 (de) 1998-04-23
NO934610L (no) 1993-12-14
NO934609L (no) 1993-12-14
DE69217056T2 (de) 1997-06-05
IE80548B1 (en) 1998-09-09
WO1993000929A1 (fr) 1993-01-21
SK279946B6 (sk) 1999-06-11
YU48913B (sh) 2002-11-15
EP0522937A1 (fr) 1993-01-13
EP0522936A1 (fr) 1993-01-13
DK0593656T5 (da) 2010-01-11
CA2102778C (fr) 2004-04-20
EP0593656B3 (fr) 2009-10-07
HK1006207A1 (en) 1999-02-12
CA2102778A1 (fr) 1993-01-09
HUT65960A (en) 1994-08-29
CZ3294A3 (en) 1995-02-15
DE69223624D1 (de) 1998-01-29
MX9203960A (es) 1993-01-01
HU217839B (hu) 2000-04-28
SE0593656T3 (no) 1997-01-22
FI940074A0 (fi) 1994-01-07
FI111807B (fi) 2003-09-30
HU9400052D0 (en) 1994-05-30
DK0593601T3 (da) 1998-02-09
TW577752B (en) 2004-03-01
AU2278792A (en) 1993-02-11
ES2110003T3 (es) 1998-02-01
ZA924999B (en) 1993-04-28
GR3025714T3 (en) 1998-03-31
CZ280965B6 (cs) 1996-05-15
SG80541A1 (en) 2001-05-22
FR2678833B1 (fr) 1995-04-07
IE80461B1 (en) 1998-07-29
MX9203959A (es) 1993-01-01
DE69217056T3 (de) 2010-04-22
KR0136722B1 (ko) 1998-04-25
PL169372B1 (en) 1996-07-31
EP0593656B1 (fr) 1997-01-22

Similar Documents

Publication Publication Date Title
NO934609D0 (no) Nye preparater basert pa derivater fra taxanklassen
NO952151D0 (no) Injiserbare, taxanderivat-baserte preparater
DE59009351D1 (de) Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel.
FI935464A (fi) Klorfluorkolfria aerosolformulationer
IT1275936B1 (it) Derivati della 10-deacetilbaccatina iii e della 10-deacetil-14b- idrossibaccatina iii loro metodo di preparazione e formulazioni
NO923721D0 (no) 4-desoksy-4-epipodophyllotoxin-derivat eller farmasoeytiskakseptabelt salt derav
ITMI931582A0 (it) Nuovi derivati del 2,2,6,6-tetrametil-4-piperidinolo utili come stabilizzanti alla luce ed all'ossidazione per materiali organici.
DE69201302D1 (de) Therapeutische zusammenstellungen auf der basis von 1,2-dithiole-3-thionderivaten.
YU31191A (sh) Novi derivati beta-fenilizoserina njegovo dobijanje i primena
ITMI911845A1 (it) Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
FI904932A (fi) Optiskt aktiva tiazetokinolin-3 -karboxylsyraderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska kompositioner.
NL7602363A (nl) N.n'-difenylguanidinederivaten.
JPS5283776A (en) Novel bicyclo 11,3,0 hexadeca-3-ene derivative
ATE1011T1 (de) 5-fluoruracil-derivate, deren herstellung und ihre pharmazeutischen zusammensetzungen.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees